Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kyntra Bio (KYNB) EBITDA (2016 - 2025)

Historic EBITDA for Kyntra Bio (KYNB) over the last 12 years, with Q3 2025 value amounting to -$5.4 million.

  • Kyntra Bio's EBITDA rose 8865.43% to -$5.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$39.5 million, marking a year-over-year increase of 8342.33%. This contributed to the annual value of -$150.4 million for FY2024, which is 5339.13% up from last year.
  • As of Q3 2025, Kyntra Bio's EBITDA stood at -$5.4 million, which was up 8865.43% from -$12.1 million recorded in Q2 2025.
  • In the past 5 years, Kyntra Bio's EBITDA registered a high of $51.0 million during Q3 2021, and its lowest value of -$135.2 million during Q4 2021.
  • Over the past 5 years, Kyntra Bio's median EBITDA value was -$63.5 million (recorded in 2023), while the average stood at -$57.6 million.
  • Its EBITDA has fluctuated over the past 5 years, first crashed by 28373.48% in 2022, then surged by 9249.96% in 2024.
  • Kyntra Bio's EBITDA (Quarter) stood at -$135.2 million in 2021, then skyrocketed by 51.09% to -$66.2 million in 2022, then plummeted by 43.76% to -$95.1 million in 2023, then surged by 92.5% to -$7.1 million in 2024, then increased by 24.14% to -$5.4 million in 2025.
  • Its EBITDA was -$5.4 million in Q3 2025, compared to -$12.1 million in Q2 2025 and -$14.9 million in Q1 2025.